-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lerodalcibep in Heterozygous familial hypercholesterolemia (heFH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Lerodalcibep in Heterozygous familial hypercholesterolemia (heFH) Drug Details: Lerodalcibep is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lerodalcibep in Homozygous Familial Hypercholesterolemia (HoFH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lerodalcibep in Homozygous Familial Hypercholesterolemia (HoFH) Drug Details: Lerodalcibep is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AWT-008 in Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AWT-008 in Lymphoma Drug Details:AWT-008 (JS-014) is under development for the treatment of solid tumors and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AT-03 in Primary Systemic Amyloidosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.AT-03 in Primary Systemic AmyloidosisDrug Details:AT-03 is under development for the treatment of ATTR (transthyretin) and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tiomolibdate Diammonium in Triple-Negative Breast Cancer (TNBC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Tiomolibdate Diammonium in Triple-Negative Breast Cancer (TNBC)Drug Details:Tiomolybdate (Coprexa)is under development for the treatment of triple...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RLYB-116 in Paroxysmal Nocturnal Hemoglobinuria
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.RLYB-116 in Paroxysmal Nocturnal Hemoglobinuria Drug Details:RLYB-116 is under development for the treatment of paroxysmal nocturnal...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RLYB-116 in Myasthenia Gravis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.RLYB-116 in Myasthenia Gravis Drug Details:RLYB-116 is under development for the treatment of paroxysmal nocturnal hemoglobinuria...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tranexamic acid in Postoperative Ileus
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Tranexamic acid in Postoperative IleusDrug Details:Tranexamic acid (LB-1148) is under development for the treatment of intra-abdominal...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HPN-536 in Fallopian Tube Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.HPN-536 in Fallopian Tube CancerDrug Details:HPN-536 is under development for the treatment of MSLN-expressing solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HPN-536 in Malignant Pleural Mesothelioma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.HPN-536 in Malignant Pleural MesotheliomaDrug Details:HPN-536 is under development for the treatment of MSLN-expressing solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HPN-536 in Peritoneal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.HPN-536 in Peritoneal CancerDrug Details:HPN-536 is under development for the treatment of MSLN-expressing solid tumors like...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HPN-536 in Epithelial Ovarian Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.HPN-536 in Epithelial Ovarian CancerDrug Details:HPN-536 is under development for the treatment of MSLN-expressing solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HPN-328 in Thymic Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.HPN-328 in Thymic CarcinomaDrug Details:HPN-328 is under development for the treatment of small-cell lung cancer, neuroendocrine...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HPN-328 in Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.HPN-328 in Colorectal Cancer Drug Details:HPN-328 is under development for the treatment of small-cell lung cancer,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HPN-217 in Refractory Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.HPN-217 in Refractory Multiple Myeloma Drug Details:HPN-217 is under development for the treatment of relapsed and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HPN-328 in Prostate Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.HPN-328 in Prostate Cancer Drug Details:HPN-328 is under development for the treatment of small-cell lung cancer,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HPN-536 in Pancreatic Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.HPN-536 in Pancreatic Cancer Drug Details:HPN-536 is under development for the treatment of MSLN-expressing solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HPN-328 in Pancreatic Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.HPN-328 in Pancreatic Cancer Drug Details:HPN-328 is under development for the treatment of small-cell lung cancer,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ND-021 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data. ND-021 in Solid Tumor Drug Details: ND-021 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HPN-217 in Relapsed Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.HPN-217 in Relapsed Multiple Myeloma Drug Details:HPN-217 is under development for the treatment of relapsed and...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.